文献速递冠心病血脂与心血管预防

IMPROVE-IT:糖尿病患者加用依折麦布的心血管获益与安全性

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
PubMed 文献 · Circulation · 2017-12-20

糖尿病患者加用依折麦布使 7 年主要终点绝对降低 5.5%(HR 0.85,95%CI 0.78–0.94),非糖尿病患者绝对降低 0.7%(HR 0.98,95%CI 0.91–1.04),交互作用 P=0.02。

要点

  • 糖尿病患者加用依折麦布显著降低主要复合终点,绝对获益 5.5%。
  • 非糖尿病患者整体获益不显著,但高风险评分者仍有 18% 相对降低。
  • 无论是否合并糖尿病,加用依折麦布未增加安全性事件。

核心结论

  • 在 IMPROVE-IT 中,急性冠脉综合征后患者加用依折麦布的心血管获益在糖尿病患者中增强,在非糖尿病高风险患者中亦增强。

主要发现

  • 糖尿病患者 4933 例(27%),较非糖尿病患者更年长、女性更多、既往心肌梗死和血运重建更多、非 ST 段抬高型急性冠脉综合征更常见(每项 P<0.001)。
  • 糖尿病患者入院低密度脂蛋白胆固醇中位数更低(89 对 97 mg/dL,P<0.001)。
  • 依折麦布/辛伐他汀组低密度脂蛋白胆固醇中位时间加权平均值显著低于安慰剂/辛伐他汀组,无论是否合并糖尿病(糖尿病:49 对 67 mg/dL;非糖尿病:55 对 71 mg/dL;均 P<0.001)。
  • 糖尿病患者依折麦布/辛伐他汀使 7 年 Kaplan-Meier 主要终点事件率绝对降低 5.5%(HR 0.85,95%CI 0.78–0.94);非糖尿病患者绝对降低 0.7%(HR 0.98,95%CI 0.91–1.04;交互作用 P=0.02)。
  • 糖尿病患者中相对降低最大者为心肌梗死(24%)和缺血性卒中(39%);无论是否合并糖尿病,安全性结局无治疗差异。

关键数值与推荐

  • 年龄≥75 岁患者主要终点相对降低 20%,无论是否合并糖尿病(交互作用 P=0.91)。
  • 年龄<75 岁糖尿病患者较非糖尿病患者获益更大(交互作用 P=0.011)。
  • 按 TIMI 二级预防风险评分分层,所有糖尿病患者均从依折麦布/辛伐他汀获益;非糖尿病高风险评分者心血管死亡、心肌梗死和缺血性卒中复合终点相对降低 18%,低/中风险者无获益(交互作用 P=0.034)。

临床怎么用

  • 急性冠脉综合征后糖尿病患者可考虑在辛伐他汀基础上加用依折麦布以进一步降低心血管事件风险。
  • 非糖尿病患者应评估二级预防风险评分,高风险者可考虑加用依折麦布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ezetimibe, when added to simvastatin, reduces cardiovascular events after acute coronary syndrome. We explored outcomes stratified by diabetes mellitus (DM). METHODS: In IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), 18 144 patients after acute coronary syndrome with low-density lipoprotein cholesterol 50 to 125 mg/dL were randomized to 40 mg ezetimibe/simvastatin (E/S) or 40 mg placebo/simvastatin. The primary composite end point was cardiovascular death, major coronary events, and stroke. DM was a prespecified subgroup. RESULTS: The 4933 (27%) patients with DM were more often older and female, had had a prior myocardial infarction and revascularization, and presented more frequently with non-ST segment elevation acute coronary syndrome compared with patients without DM (each P<0.001). The median admission low-density lipoprotein cholesterol was lower among patients with DM (89 versus 97 mg/dL, P<0.001). E/S achieved a significantly lower median time-weighted average low-density lipoprotein cholesterol compared with placebo/simvastatin, irrespective of DM (DM: 49 versus 67 mg/dL; no DM: 55 versus 71 mg/dL; both P<0.001). In patients with DM, E/S reduced the 7-year Kaplan-Meier primary end point event rate by 5.5% absolute (hazard ratio, 0.85; 95% confidence interval, 0.78-0.94); in patients without DM, the absolute difference was 0.7% (hazard ratio, 0.98; 95% confidence interval, 0.91-1.04; Pint=0.02). The largest relative reductions in patients with DM were in myocardial infarction (24%) and ischemic stroke (39%). No differences in safety outcomes by treatment were present regardless of DM. When stratified further by age, patients ≥75 years of age had a 20% relative reduction in the primary end point regardless of DM (Pint=0.91), whereas patients <75 years of age with DM had greater benefit than those without (Pint=0.011). When stratified by the TIMI (Thrombolysis in Myocardial Infarction) Risk Score for Secondary Prevention, all patients with DM demonstrated benefit with E/S regardless of risk. In contrast, among patients without DM, those with a high risk score experienced a significant (18%) relative reduction in the composite of cardiovascular death, myocardial infarction, and ischemic stroke with E/S compared with placebo/simvastatin, whereas patients without DM at low or moderate risk demonstrated no benefit with the addition of ezetimibe to simvastatin (Pint =0.034). CONCLUSIONS: In IMPROVE-IT, the benefit of adding ezetimibe to statin was enhanced in patients with DM and in high-risk patients without DM. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00202878.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017. PMID: 29263150. doi:10.1161/CIRCULATIONAHA.117.030950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。